| Ibrutinib | None | ||
| 70MG, 140MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| IMBRUVICA is a kinase inhibitor indicated for the treatment of adult patients with: • Mantle cell lymphoma (MCL) who have received at least one prior therapy. • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL). • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion. • Waldenström’s macroglobulinemia (WM). • Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. • Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy. | |||
|
Yes
| |||
| Imbruvica | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 | Patent 27 | Patent 28 | Patent 29 | Patent 30 | Patent 31 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||||||||||||||||||||||||||||||||||
| ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | ******* ** ******** *** ********** ***** ****** **** ******* | ******* ** ******** *** ********** ***** ****** **** ******* | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | ******* ** ******** *** ********** ***** ****** **** ******* | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | ******* ** ******** *** ********** ***** ****** **** ******* | *** ** ********** ** ******'* ******** ****** (***) | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *** ** ********** ** ******* ******** ****** (***) | ************/************ ********** ********* | ************ ********** ********* |
| Ibrutinib | None | ||
| 70MG/1ML |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| IMBRUVICA is a kinase inhibitor indicated for the treatment of adult patients with: • Mantle cell lymphoma (MCL) who have received at least one prior therapy. • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL). • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion. • Waldenström’s macroglobulinemia (WM). • Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. • Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy. | |||
|
Yes
| |||
| Imbruvica | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 | Patent 27 | Patent 28 | Patent 29 | Patent 30 | Patent 31 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||||||||||||||||||||||||||||||||||
| ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | ******* ** ******** *** ********** ***** ****** **** ******* | ******* ** ******** *** ********** ***** ****** **** ******* | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | ******* ** ******** *** ********** ***** ****** **** ******* | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | ******* ** ******** *** ********** ***** ****** **** ******* | *** ** ********** ** ******'* ******** ****** (***) | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *** ** ********** ** ******* ******** ****** (***) | ************/************ ********** ********* | ************ ********** ********* |
| Ibrutinib | None | ||
| 140MG, 230MG, 420MG, 560MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| IMBRUVICA is a kinase inhibitor indicated for the treatment of adult patients with: • Mantle cell lymphoma (MCL) who have received at least one prior therapy. • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL). • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion. • Waldenström’s macroglobulinemia (WM). • Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. • Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy. | |||
|
Yes
| |||
| Imbruvica | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 | Patent 27 | Patent 28 | Patent 29 | Patent 30 | Patent 31 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||||||||||||||||||||||||||||||||||
| ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | ********** ** ******'* ******** ****** | ********** ** ******'* ******** ****** | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | ******* ** ******** *** ********** ***** ****** **** ******* | ******* ** ******** *** ********** ***** ****** **** ******* | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | ******* ** ******** *** ********** ***** ****** **** ******* | *** ** ********** ** ******'* ******** ****** (***) | *** ** ********** ** ******'* ******** ****** (***) | ******* ** ******** *** ********** ***** ****** **** ******* | *** ** ********** ** ******'* ******** ****** (***) | *********** ***** ** * ******'* ******** ****** ********* | *********** ***** ** * ******'* ******** ****** ********* | *** ** ********** ** ******* ******** ****** (***) | ************/************ ********** ********* | ************ ********** ********* |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|